Sergey Aksenov
Sergey Aksenov
Подтвержден адрес электронной почты в домене astrazeneca.com
Название
Процитировано
Процитировано
Год
A spatially extended stochastic model of the bacterial chemotaxis signalling pathway
TS Shimizu, SV Aksenov, D Bray
Journal of molecular biology 329 (2), 291-309, 2003
1872003
A systems biology dynamical model of mammalian G1 cell cycle progression
T Haberichter, B Mädge, RA Christopher, N Yoshioka, A Dhiman, R Miller, ...
Molecular systems biology 3 (1), 84, 2007
762007
Dynamics of the inducing signal for the SOS regulatory system in Escherichia coli after ultraviolet irradiation
SV Aksenov
Mathematical biosciences 157 (1-2), 269-286, 1999
351999
An integrated approach for inference and mechanistic modeling for advancing drug development
SV Aksenov, B Church, A Dhiman, A Georgieva, R Sarangapani, ...
FEBS letters 579 (8), 1878-1883, 2005
342005
Application of the combined nonlinear-condensation transformation to problems in statistical analysis and theoretical physics
SV Aksenov, MA Savageau, UD Jentschura, J Becher, G Soff, PJ Mohr
Computer physics communications 150 (1), 1-20, 2003
332003
Mathematical Model of the SOS Response Regulation of an Excision Repair Deficient Mutant ofEscherichia coliafter Ultraviolet Light Irradiation
SV Aksenov, EA Krasavin, AA Litvin
Journal of theoretical biology 186 (2), 251-260, 1997
181997
Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
G Burian, S Aksenov
US Patent App. 14/903,749, 2016
132016
Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
G Burian, S Aksenov
US Patent App. 14/903,435, 2016
132016
Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet
G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ...
European Journal of Pharmaceutical Sciences 109, S39-S46, 2017
112017
Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients
L Ting, S Aksenov, SG Bhansali, R Ramakrishna, P Tang, DE Geller
CPT: pharmacometrics & systems pharmacology 3 (2), 1-7, 2014
112014
Induction of the SOS response in ultraviolet-irradiated Escherichia coli analyzed by dynamics of LexA, RecA and SulA proteins
SV Aksenov
Journal of biological physics 25 (2), 263-277, 1999
111999
Some properties of the Lerch family of discrete distributions
SV Aksenov, MA Savageau
arXiv preprint math/0504485, 2005
92005
Pharmacometric modeling of naloxegol efficacy and safety: impact on dose and label
N Al‐Huniti, D Zhou, H Xu, S Aksenov, KH Bui, R Fox, G Helmlinger, ...
Clinical Pharmacology & Therapeutics 102 (5), 741-744, 2017
82017
Mathematica and C programs for minimum distance estimation of the S distribution and for calculation of Goodness-of-Fit by bootstrap
SV Aksenov, MA Savageau
press, 2001
72001
Individualized treatment strategies for hyperuricemia informed by a semi‐mechanistic exposure‐response model of uric acid dynamics
S Aksenov, CC Peck, UG Eriksson, DR Stanski
Physiological reports 6 (5), e13614, 2018
52018
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis
B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ...
Oncoimmunology 9 (1), 1748982, 2020
42020
Population pharmacokinetics of the BTK inhibitor acalabrutinib and its active metabolite in healthy volunteers and patients with B-cell malignancies
H Edlund, SK Lee, MA Andrew, JG Slatter, S Aksenov, N Al-Huniti
Clinical pharmacokinetics 58 (5), 659-672, 2019
42019
Modeling tumor growth and treatment resistance dynamics characterizes different response to gefitinib or chemotherapy in non‐small cell lung cancer
M Nagase, S Aksenov, H Yan, J Dunyak, N Al‐Huniti
CPT: pharmacometrics & systems pharmacology 9 (3), 143-152, 2020
22020
Comparison of different approaches to modeling early tumor size dynamics for accurate prediction of survival in non-small cell lung cancer (NSCLC) clinical trials
Y Kosinsky, I Azarov, L Chu, G Helmlinger, K Peskov, S Aksenov
Journal of Pharmacokinetics and Pharmacodynamics 45, S123-S123, 2018
22018
Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
N Al‐Huniti, H Xu, D Zhou, S Aksenov, R Fox, KH Bui
CPT: pharmacometrics & systems pharmacology 6 (10), 705-711, 2017
22017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20